UNLABELLED: N-acetylcysteine (NAC) is a thiol donor with antioxidant properties that has potential use as an ergogenic aid. However, NAC is associated with adverse reactions that limit its use in humans. PURPOSE: The authors evaluated NAC efficacy as a thiol donor before handgrip exercise, measuring changes in serum cysteine and glutathione status and recording adverse reactions in adult subjects across a range of doses. METHODS: Healthy individuals ingested NAC capsules (9 ± 2 or 18 ± 4 mg/kg) or solution (0, 35, 70, or 140 mg/kg). Venous blood samples were collected and subjects answered a questionnaire about adverse reactions. RESULTS: Low doses of NAC (capsules) did not affect plasma cysteine or glutathione or cause adverse reactions. Adverse reactions to NAC solution were predominantly mild and gastrointestinal (GI). Intensity of GI reactions to 140 mg/kg NAC was significantly higher than placebo (in a.u., 0.67 ± 0.16 vs. 0.07 ± 0.04; p < .05). Plasma cysteine concentration increased with NAC dose from 9.3 ± 0.7 μM (placebo) to 65.3 ± 6.7 μM (140 mg/kg); however, there was no difference (p > .05) in plasma cysteine for 70 mg/kg vs. 140 mg/kg. Similar increases were observed for the ratio of cysteine to total cysteine, which was directly related to handgrip exercise performance. Plasma glutathione was elevated and oxidized glutathione diminished (p < .05) with NAC 140 mg/kg vs. placebo. CONCLUSION: NAC effects on plasma thiols are maximized by oral administration of 70 mg/kg, a dose that does not cause significant adverse reactions.
RCT Entities:
UNLABELLED: N-acetylcysteine (NAC) is a thioldonor with antioxidant properties that has potential use as an ergogenic aid. However, NAC is associated with adverse reactions that limit its use in humans. PURPOSE: The authors evaluated NAC efficacy as a thioldonor before handgrip exercise, measuring changes in serum cysteine and glutathione status and recording adverse reactions in adult subjects across a range of doses. METHODS: Healthy individuals ingested NAC capsules (9 ± 2 or 18 ± 4 mg/kg) or solution (0, 35, 70, or 140 mg/kg). Venous blood samples were collected and subjects answered a questionnaire about adverse reactions. RESULTS: Low doses of NAC (capsules) did not affect plasma cysteine or glutathione or cause adverse reactions. Adverse reactions to NAC solution were predominantly mild and gastrointestinal (GI). Intensity of GI reactions to 140 mg/kg NAC was significantly higher than placebo (in a.u., 0.67 ± 0.16 vs. 0.07 ± 0.04; p < .05). Plasma cysteine concentration increased with NAC dose from 9.3 ± 0.7 μM (placebo) to 65.3 ± 6.7 μM (140 mg/kg); however, there was no difference (p > .05) in plasma cysteine for 70 mg/kg vs. 140 mg/kg. Similar increases were observed for the ratio of cysteine to total cysteine, which was directly related to handgrip exercise performance. Plasma glutathione was elevated and oxidized glutathione diminished (p < .05) with NAC 140 mg/kg vs. placebo. CONCLUSION:NAC effects on plasma thiols are maximized by oral administration of 70 mg/kg, a dose that does not cause significant adverse reactions.
Authors: Michael J McKenna; Ivan Medved; Craig A Goodman; Malcolm J Brown; Andrew R Bjorksten; Kate T Murphy; Aaron C Petersen; Simon Sostaric; Xiaofei Gong Journal: J Physiol Date: 2006-07-13 Impact factor: 5.182
Authors: Gavin J Pinniger; Jessica R Terrill; Evanna B Assan; Miranda D Grounds; Peter G Arthur Journal: J Physiol Date: 2017-09-30 Impact factor: 5.182
Authors: Alexandra Sakelliou; Ioannis G Fatouros; Ioannis Athanailidis; Dimitrios Tsoukas; Athanasios Chatzinikolaou; Dimitris Draganidis; Athanasios Z Jamurtas; Christina Liacos; Ioannis Papassotiriou; Dimitrios Mandalidis; Kimon Stamatelopoulos; Meletios A Dimopoulos; Asimina Mitrakou Journal: Oxid Med Cell Longev Date: 2016-11-15 Impact factor: 6.543
Authors: Joshua R Smith; Ryan M Broxterman; Carl J Ade; Kara K Evans; Stephanie P Kurti; Shane M Hammer; Thomas J Barstow; Craig A Harms Journal: Physiol Rep Date: 2016-04